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Activated Ras, but not Raf, causes transformation of RIE-1 rat intestinal epithelial cells, demonstrating the
importance of Raf-independent effector signaling in mediating Ras transformation. To further assess the
contribution of Raf-dependent and Raf-independent function in oncogenic Ras transformation, we evaluated
the mechanism by which oncogenic Ras blocks suspension-induced apoptosis, or anoikis, of RIE-1 cells. We
determined that oncogenic versions of H-, K-, and N-Ras, as well as the Ras-related proteins TC21 and R-Ras,
protected RIE-1 cells from anoikis. Surprisingly, our analyses of Ras effector domain mutants or constitutively
activated effectors indicated that activation of Raf-1, phosphatidylinositol 3-kinase (PI3K), or RalGDS alone
is not sufficient to promote Ras inhibition of anoikis. Treatment of Ras-transformed cells with the U0126 MEK
inhibitor caused partial reversion to an anoikis-sensitive state, indicating that extracellular signal-regulated
kinase activation contributes to inhibition of anoikis. Unexpectedly, oncogenic Ras failed to activate Akt, and
treatment of Ras-transformed RIE-1 cells with the LY294002 PI3K inhibitor did not affect anoikis resistance
or growth in soft agar. Thus, while important for Ras transformation of fibroblasts, PI3K may not be involved
in Ras transformation of RIE-1 cells. Finally, inhibition of epidermal growth factor receptor kinase activity did
not overcome Ras inhibition of anoikis, indicating that this autocrine loop essential for transformation is not
involved in anoikis protection. We conclude that a PI3K- and RalGEF-independent Ras effector(s) likely
cooperates with Raf to confer anoikis resistance upon RIE-1 cells, thus underscoring the complex nature by
which Ras transforms cells.
Anoikis means “homelessness” in Greek (18). It is a term
used to describe the observation that normal epithelial cells
are dependent upon an appropriate extracellular basement
membrane, or home, to be viable. When epithelial cells lose
contact with their basement membrane, they undergo anoikis,
also known as suspension-induced apoptosis (17). This allows
the body to rid itself of cells that are no longer needed and,
presumably, protects tissues from inappropriate colonization
by nonadherent cells. In adult organisms, suspension-induced
apoptosis is commonly observed during regeneration of skin or
colonic epithelia or during involution of the mammary gland
(6, 23, 40).
Gaining resistance to anoikis may be a general prerequisite
for the development and progression of cancers of epithelial
origin, or carcinomas. Acquiring independence from adhesion
is a hallmark of the transformed cell, and most cell lines de-
rived from human tumors are capable of growing in the ab-
sence of adhesion (49). This characteristic of transformation
likely imparts a significant, and clearly abnormal, survival ad-
vantage to cells. Cells in primary tumors, for example, often
lack contact with an organized basement membrane and thus
must adapt to growth in matrix-poor or disorganized extracel-
lular environments (39). Traversing the blood and lymph sys-
tems during metastasis also requires that cells survive in the
absence of appropriate matrix contacts.
In vitro, a variety of immortalized but phenotypically normal
cell lines can be made adhesion independent by expression of
the dominant positive oncoprotein Ras. Aberrant activation of
Ras is common in human cancers, both by direct mutation and
by indirect stimulation via deregulated cell surface receptor
signaling (1, 4, 10). Thus, understanding how Ras signal trans-
duction imparts adhesion independence in vitro may reveal
crucial targets for pharmacologic intervention and cancer
treatment in vivo.
Understanding the mechanisms by which Ras promotes ad-
hesion independence is complicated by the fact that Ras signal
transduction is much more complex than originally envisioned
(51). First, there are currently over 18 known proteins that
bind Ras in its GTP-bound or activated state and thus have the
potential to serve as downstream effectors of Ras (7, 33). These
proteins include lipid kinases, protein kinases, GTPase-activat-
ing proteins, guanine nucleotide exchange factors (GEFs), and
proteins with no known enzymatic function. For many of these
proteins, it is unknown what role they play in Ras transforma-
tion. Second, oncogenic Ras can exert different biological ef-
fects depending on the genetic context in which it is expressed.
For example, while primary mouse fibroblasts undergo senes-
cence in response to activated Ras expression, the additional
loss of p53 or Rb-1 tumor suppressor function allows Ras to
cause growth transformation (22, 50). Third, the mechanisms
of Ras transformation may vary as a function of cellular con-
text. For example, the signaling pathways by which Ras causes
transformation of NIH 3T3 mouse fibroblasts and RIE-1 rat
intestinal epithelial cells are strikingly different (20, 31, 35).
While aberrant activation of the Ras effector Raf alone is
sufficient to transform fibroblasts, Raf activation alone is in-
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sufficient to transform RIE-1 cells. Furthermore, Ras transfor-
mation of RIE-1 cells is critically dependent on a Raf-inde-
pendent transforming growth factor a (TGF-a)–epidermal
growth factor receptor (EGFR) autocrine signaling mecha-
nism not required for fibroblast transformation.
Despite the complexity of Ras signal transduction, there are
three well-characterized Ras effectors that play established
roles in Ras transformation of rodent fibroblasts. The best
characterized are the Raf serine/threonine protein kinases c-
Raf-1, A-Raf, and B-Raf (7). These kinases activate MEK1/2
and in turn activate the extracellular signal-regulated kinase
(ERK) mitogen-activated protein kinases (MAPKs). The Raf-
MEK-ERK pathway has been shown to be necessary and suf-
ficient to promote Ras transformation of rodent fibroblasts.
The second best characterized effectors of Ras are the class I
phosphatidylinositol 3-kinases (PI3Ks) p110a, p110b, p110g,
and p110d (42–44). A major function for these lipid kinases is
the phosphorylation of phosphatidylinositol (4,5)-bisphosphate
(PIP2) to produce phosphatidylinositol (3,4,5)-triphosphate
(PIP3). Accumulation of PIP3 in Ras-transformed cells can
facilitate activation of the Akt/protein kinase B (PKB) protein
kinases. Akt, in turn, promotes cell survival by directly regu-
lating the machinery of apoptosis as well as by causing changes
in gene expression (12, 30, 45). PIP3 levels are elevated in
Ras-transformed rodent fibroblasts, and dominant negative
PI3K can block Ras transformation of NIH 3T3 cells (43). The
third best characterized effectors are GEFs for the Ral small
GTPases (RalGDS, Rgl, and Rlf/Rgl2) (15, 57). These proteins
stimulate formation of the active, GTP-bound forms of RalA
and RalB, and dominant negative Ral can block Ras transfor-
mation (54). Aside from these three main classes of effectors,
the roles of other proteins in Ras transformation are less well
characterized.
Given that ras is most commonly mutated in carcinomas (4,
10), we sought to expand our understanding of the role of Ras
in epithelial cell transformation. Previous studies had docu-
mented that oncogenic Ras blocks anoikis of MDCK canine
kidney epithelial cells (17, 29). Furthermore, it was determined
that the Ras effector PI3K and its downstream target Akt were
both necessary and sufficient for Ras-mediated anoikis protec-
tion of these cells. To assess whether these results are appli-
cable to other Ras-transformed epithelial cell lines and
whether other Ras effectors contribute to anoikis resistance,
we evaluated the mechanism of anoikis resistance in Ras-trans-
formed RIE-1 epithelial cells. Surprisingly, we found that
PI3K-Akt signaling was neither necessary nor sufficient for
Ras-mediated anoikis resistance, or growth transformation, of
RIE-1 cells. Instead, we determined that anoikis resistance of
Ras-transformed RIE-1 cells is complex and caused by the
combined actions of Raf and an unknown PI3K- and RalGEF-
independent effector(s). Cumulatively, these data indicate that
the Ras oncoprotein has multiple signaling properties that
promote anoikis resistance and transformation of epithelial cells.
MATERIALS AND METHODS
Molecular constructs. cDNA sequences encoding constitutively activated Ras
proteins [H-Ras(12V), H-Ras(61L), K-Ras(12V), and N-Ras(13D)]; activated
Ras-related proteins [TC21(23V) and R-Ras(38V)]; hemagglutinin (HA)
epitope-tagged and activated Rho family GTPases [Rac1(61L) and RhoA(63L)];
and activated Ras effectors Raf-1 (Raf-22W and Raf-CAAX), PI3K (p110-
CAAX), and RalGDS (RalGDS-CAAX) and HA-tagged Rlf (HA-Rlf-CAAX)
were cloned into the BamHI or EcoRI sites of the pBabe-puro and pZIP-
NeoSV(x)1 retroviral expression vectors. The amino acid substitutions shown for
the GTPases render them constitutively GTP bound and thus activated. Activa-
tion of Raf-1 was achieved by NH2-terminal truncation (designated Raf-22W) or
membrane targeting (Raf-CAAX) (52) and the PI3K, RalGDS, and Rlf were
activated by addition of the COOH-terminal plasma membrane targeting se-
quences from H- or K-Ras4B and designated p110-CAAX (43), RalGDS-CAAX
(41), and HA-Rlf-CAAX (58), respectively. These Ras sequences signal post-
translational modifications that cause constitutive membrane localization. Mem-
brane localization, in turn, promotes activation of the catalytic functions of Raf-1
and p110. The pDCR eukaryotic expression vectors encoding effector domain
mutants of H-Ras(12V) (provided by M. White), which are impaired in specific
effector interactions, have been described previously (28, 43, 56). In brief, the
E37G mutant retains binding of RalGEFs but is reduced in its ability to bind Raf
or PI3K. Similarly, the Y40C mutant retains PI3K binding but is reduced in Raf
and RalGEF binding, while the T35S mutant retains Raf binding but is reduced
in PI3K and RalGEF binding.
Inhibitors. Chemical inhibitors used in this study are specific to MEK1/2
(U0126) (provided by J. Trzaskos, Dupont) (13), PI3K (LY294002) (A.G. Sci-
entific) (55), caspase-1-like proteases (Z-VAD-FMK) (Calbiochem) (14), and
the EGFR kinase (PD153035) (Tocris Cookson) (19). All inhibitors were dis-
solved in dimethyl sulfoxide for use, and their effects were measured relative to
dimethyl sulfoxide (vehicle)-treated controls.
Cell culture, retroviral infection, and transfection. RIE-1 cells were obtained
from Robert J. Coffey (Vanderbilt University, Nashville, Tenn.) (3). RIE-1 or
Bosc23 and ROSE 199 cells (provided by R. Schäfer) were grown in Dulbecco’s
modified Eagle’s medium supplemented with 5 or 10% fetal calf serum, respec-
tively. Mass populations of stably infected [pBabe-puro and pZIP-NeoSV(x)1] or
transfected (pDCR) cell populations were selected by the supplementation of
the growth medium with 400 mg of G418/ml [for pDCR and pZIP-NeoSV(x)1
expression constructs] or 2 mg of puromycin/ml (for pBabe-puro expression
constructs).
Production of infectious, replication-incompetent retrovirus was achieved by
transfection of pZIP-NeoSV(x)1 and pBabe-puro expression constructs into the
Bosc23 ecotropic packaging cell line (37). RIE-1 cells seeded 24 h in advance at
a density of 105 cells per 60-mm dish were infected by exposure to 1.5 ml of
retroviral supernatant, together with 1.5 ml of growth medium, and Polybrene
was added to a final concentration of 4 mg/ml. After 5 h, fresh growth medium
was added, and drug selection was initiated 24 h later. Cells expressing pDCR
constructs were obtained by transfection with Effectene per the manufacturer’s
instructions (Qiagen).
SDS-polyacrylamide gel electrophoresis and Western blot analyses. Cell ly-
sates were generated by lysis directly into sodium dodecyl sulfate (SDS) sample
buffer (for Akt analysis) or buffer containing 20 mM Tris (pH 7.4), 0.5% NP-40,
and 250 mM NaCl (for Akt analysis and other analyses). The latter lysates were
clarified by centrifugation at 12,000 3 g for 10 min at 4°C prior to use. Proteins
were separated by SDS-polyacrylamide gel electrophoresis in 14, 7.5, or 10%
gels; transferred to Immobilon P (Millipore) membranes; and incubated with
primary antibodies per the manufacturer’s instructions. Antibodies used for
immunoblotting are specific to ERK (sc93R; Santa Cruz Biotechnology), Akt,
phospho-Akt, phospho-ERK (New England Biolabs, Inc./Cell Signaling Tech-
nology), Ras (LA045; Viromed Biosafety), and the HA epitope tag (BabCO).
Secondary antibodies were either horseradish peroxidase or alkaline phospha-
tase conjugated for detection by enhanced chemiluminescence (Amersham Phar-
macia Biotech) or phosphorimaging (Molecular Dynamics), respectively.
Apoptosis assays. RIE-1 cells were plated 36 h in advance of suspension at a
density of 4 3 106 cells per T185 flask (Nalge Nunc). To suspend cells, cells were
treated with 0.25% trypsin dissolved in phosphate-buffered saline containing 2.5
mM EDTA for 8 min at 37°C. Cells were washed with either growth medium or
0.5 mg of soybean trypsin inhibitor (Sigma)/ml depending on whether cells were
to be suspended in growth medium or in Dulbecco’s modified Eagle’s medium
supplemented with 0.5 mg of bovine serum albumin/ml, respectively.
Cells were plated in poly(2-hydroxyethyl methacrylate) (poly-HEME)-coated
dishes, prepared as described previously, in the presence of growth medium
unless otherwise noted (17). Treatment with the LY294002 inhibitor involved
suspending cells in the absence of serum for 30 min prior to the addition of 10
mM LY294002. After an additional 30 min of incubation, cells were stimulated
with 5% fetal bovine serum when indicated. The MEK and EGFR kinase inhib-
itors were used at 30 and 2 mM, respectively, and added to cells after a 30-min
incubation in growth medium in suspension.
We used three types of assays to measure anoikis: DNA laddering, [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
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tetrazolium) (MTS) tetrazolium-based viability assays, and DNA fragmentation
enzyme-linked immunosorbent assay (ELISA). For viability assays, 106 cells were
suspended in poly-HEME-coated petri dishes for 15 h prior to replating a
fraction of the suspended samples in 96-well dishes. Viability was measured by
the conversion of MTS tetrazolium to formazan per the manufacturer’s instruc-
tions (CellTiter AQueous kit; Promega). For DNA fragmentation ELISA, cells
were suspended as described above and subsequently lysed in 1.5 ml of a lysis
buffer containing 10 mM Tris (pH 8.0), 10 mM EDTA, and 0.5% Tx-100. Twenty
microliters of this lysate was analyzed as recommended by the manufacturer
(DNA Death ELISA 10x; Boehringer Mannheim). For DNA laddering, 3 3 106
cells were processed by extraction and processing of low-molecular-weight DNA
essentially as described previously (29). In brief, cells were lysed in the same
buffer used for DNA fragmentation ELISAs. Subsequently, the soluble fraction
was subjected to phenol-chloroform extraction and RNase A treatment prior to
electrophoresis of the samples in a 1.5% agarose gel.
Soft agar colony formation. To assess growth of RIE-1 cells in soft agar, cells
were seeded at 103 to 104 cells per 60-mm dish in growth medium containing
0.3% agar over a base layer of 0.6% agar (9). LY294002 was added at a final
concentration of 10 mM when indicated.
RESULTS
Oncogenic Ras promotes anoikis resistance of RIE-1 cells.
Previous studies showed that oncogenic Ras conferred anoikis
resistance upon MDCK canine kidney epithelial cells (17, 29).
It was determined that Ras activation of PI3K, and not Raf,
was necessary and sufficient to block anoikis. We showed pre-
viously that oncogenic Ras caused anchorage-independent
growth of RIE-1 rat intestinal epithelial cells by activation of
Raf-dependent and Raf-independent effectors (35). Further-
more, we determined that the anchorage-independent growth
of Ras-transformed RIE-1 cells was also dependent on the
activation of TGF-a via Raf-dependent and Raf-independent
pathways (20). These observations suggested that Ras may
block anoikis, a critical requirement for anchorage-indepen-
dent growth, by a more complex mechanism in RIE-1 cells.
Therefore, we initiated studies to determine if oncogenic Ras
rendered RIE-1 cells insensitive to anoikis, and if so, what
effectors were important in mediating this activity.
We first determined if untransformed RIE-1 cells responded
to loss of matrix attachment by undergoing anoikis. We utilized
three assays to evaluate this. The first indirectly measures
anoikis by quantitating decreases in cellular viability. The sec-
ond is specific to apoptosis and visualizes internucleosomal
DNA degradation as a “ladder” of low-molecular-weight DNA
in agarose gels. The third quantitates DNA fragmentation that
results from apoptosis by ELISA. As shown in Fig. 1, RIE-1
cells suffered a dramatic loss of cell viability when held in
suspension for 12 h (Fig. 1A). Loss of viability was a conse-
quence of detachment-induced apoptosis (Fig. 1B). DNA frag-
mentation in response to suspension was blocked by treatment
with a general caspase inhibitor, Z-VAD-FMK, indicating that
RIE-1 cells underwent apoptosis in a caspase-dependent man-
ner (Fig. 1C).
To determine whether oncogenic Ras is capable of inhibiting
anoikis of RIE-1 cells, expression plasmids encoding constitu-
tively active versions of the three Ras proteins, H-Ras(12V),
N-Ras(13D), and K-Ras4B(12V), were introduced by retrovi-
ral infection followed by drug selection to establish mass pop-
ulations of RIE-1 cells stably expressing activated Ras. The
resulting cell populations were suspended and assayed for ap-
optosis and viability. All oncogenic versions of Ras blocked
anoikis of RIE-1 cells (Fig. 1A and B). Thus, while differences
in the function of Ras proteins have been described previously
(51), no differences were seen for inhibition of anoikis.
We also evaluated the ability of other Ras superfamily
GTPases to protect RIE-1 cells from anoikis. Activated forms
of the Ras family proteins R-Ras and TC21/R-Ras2 and the
Rho family proteins RhoA and Rac1 have been shown previ-
ously to promote the anchorage-independent growth of NIH
FIG. 1. Ras blocks anoikis of RIE-1 cells. (A and B) RIE-1 cells stably expressing activated H-, K-, or N-Ras proteins were analyzed for viability
by the MTS assay after being held in suspension for 15 h (A) or 12 h prior to assessing apoptosis by DNA laddering (B). (C) Cells stably infected
with vector were incubated with vehicle or a broad-spectrum caspase inhibitor for 15 h in suspension prior to assessing apoptosis by DNA
fragmentation ELISA. Data shown are representative of at least two independent experiments. Bars represent the standard deviations resulting
from triplicate samples (A) or duplicate reading of the same sample (C).
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3T3 cells (11, 27). We found that RIE-1 cells stably expressing
activated R-Ras and TC21, but not RhoA or Rac1, were also
resistant to anoikis (Fig. 2). Since we showed previously that
R-Ras and TC21 are not activators of Raf (21, 26), these
results suggest that Ras activation of Raf is not required for
inhibition of anoikis. Support for this conclusion was also pro-
vided by our observation that ERK activation was seen in
suspended RIE-1 cells expressing activated Ras, but not R-Ras
or TC21 (data not shown).
Ras activation of the Raf, PI3K, or RalGEF effector path-
ways is not sufficient to promote anoikis resistance. Oncogenic
Ras signals through multiple effectors, including PI3K, Raf,
and RalGEFs. We sought to determine if activation of indi-
vidual Ras effector signaling pathways was sufficient to block
anoikis of Ras-transformed RIE-1 cells. To do this, we first
evaluated the ability of effector domain mutants of activated
H-Ras(12V), which are differentially impaired in effector uti-
lization, to block anoikis (28, 43, 56). The H-Ras(12V/35S)
mutant retains the ability to activate Raf but not PI3K or
RalGDS. The H-Ras(12V/37G) mutant no longer activates
Raf or PI3K but can activate RalGDS and related proteins.
The H-Ras(12V/40C) mutant retains the ability to activate
PI3K but no longer activates Raf or RalGDS. Surprisingly,
mass populations of RIE-1 cells stably expressing the three Ras
effector domain mutants were as sensitive to anoikis as were
the empty vector-infected control RIE-1 cells (Fig. 3B). This
result suggests that Ras activation of Raf, PI3K, or RalGDS
alone is not sufficient to block anoikis.
To further evaluate whether activation of different effectors
of Ras is sufficient to block anoikis, we also established RIE-1
cells stably expressing constitutively activated versions of Raf,
PI3K, or two RalGEF family members, RalGDS and Rlf. Sim-
ilar to what had been observed previously with MDCK cells
(29), expression of the amino-terminally truncated and consti-
tutively activated mutant of the Raf-1 kinase (Raf-22W) did
not protect RIE-1 cells from anoikis. While RIE-1 cells ex-
pressing Raf-22W had elevated levels of activated ERK in
suspension (Fig. 4A), these cells were not anoikis resistant as
FIG. 2. Unlike Ras and Ras-related proteins, activated Rho family members fail to protect RIE-1 cells from anoikis. (A) RIE-1 cells stably
expressing Rac1(61L), RhoA(63L), TC21(72L), R-Ras(38V), or K-Ras4B(12V) were evaluated for viability in response to a 15-h suspension by
the MTS viability assay. (B) The cells described for panel A and H-Ras(61L)-expressing cells were also evaluated for apoptosis by DNA
fragmentation ELISA. Data shown are representative of two independent experiments. Bars represent the standard deviations resulting from
triplicate samples (A) or duplicate reading of the same sample (B).
FIG. 3. Effector domain mutants of H-Ras(12V) fail to block
anoikis. (A) RIE-1 cells stably infected with H-Ras(12V), H-Ras(12V/
S35), H-Ras(12V/G37), or H-Ras(12V/C40) were assayed for Ras ex-
pression levels by Western blot analysis with pan-Ras antibody. The
upper band represents the HA epitope-tagged exogenous H-Ras(12V)
proteins, and the lower band represents endogenous Ras proteins. (B)
The cell populations described for panel A were held in suspension for
the indicated time (hours) prior to assessing anoikis by DNA ladder-
ing. WT, wild type.
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determined by both a viability assay and an apoptosis-specific
DNA fragmentation ELISA (Fig. 4B and C). These results are
also consistent with our previous observation that Raf-22W-
expressing RIE-1 cells failed to form colonies in soft agar (35).
Similarly, we found that RIE-1 cells stably infected with an
expression vector encoding a plasma membrane-targeted and
constitutively activated form of RalGDS (RalGDS-CAAX)
were also sensitive to anoikis (Fig. 4D). To extend our evalu-
ation to an additional RalGEF family member, namely, Rlf, we
also expressed HA-tagged, membrane-targeted Rlf (HA-Rlf-
CAAX). HA-Rlf-CAAX expression was confirmed in sus-
pended cells by anti-HA immunoblotting (data not shown).
Activated Rlf, like RalGDS, failed to block anoikis of RIE-1
cells (Fig. 4D). When this finding is taken together with the
failure of the H-Ras(12V/37G) effector domain mutant to
block anoikis, we conclude that Ras activation of RalGEFs
alone is not sufficient to allow cells to survive in suspension.
When assessed in MDCK cells, expression of activated PI3K
(p110-CAAX) or the PI3K target Akt/PKB conferred protec-
tion against anoikis (29). To determine if PI3K activation alone
was sufficient to overcome anoikis of RIE-1 cells, we estab-
lished a mass population stably expressing a plasma mem-
brane-targeted form of the catalytic subunit of PI3K (designat-
ed p110-CAAX). Western blot analyses with phospho-specific
antibodies that recognize activated Akt verified that these cells
possessed elevated PI3K activity (Fig. 5A). However, as we had
seen with H-Ras(12V/40C), expression of activated PI3K was
not sufficient to prevent suspension-induced apoptosis (Fig.
5B). These results contrast with those made with MDCK cells,
where Akt activation alone was sufficient to block anoikis (29).
Given the central role for PI3K-Akt signaling in Ras-trans-
formed MDCK cells, we sought to determine if our results with
PI3K were not restricted to a single cell line. We thus chose to
perform anoikis studies with another epithelial model of trans-
formation, namely, the ROSE 199 rat ovarian surface epithe-
lial cell line. Mass populations of the cells expressing either
FIG. 4. Activated Raf-1 or RalGEFs alone are not sufficient to block anoikis. (A) RIE-1 cells expressing activated Raf-1 (Raf-22W) or
H-Ras(12V) were assayed for ERK activation by immunoblotting cell lysates with phospho-ERK antibodies. Cell lysates were made from cells
suspended for 6 h. Blots were stripped and reprobed with anti-ERK antibodies. (B and C) The Raf-expressing RIE-1 cells were evaluated for
anoikis resistance after suspension for 8 or 15 h by performing DNA fragmentation ELISA (B) or an MTS assay (C), respectively. (D) RIE-1 cells
stably infected with membrane-targeted and constitutively activated RalGDS protein, RalGDS-CAAX, or Rlf protein, HA-Rlf-CAAX, were
maintained in suspension for 12 h and subsequently analyzed for anoikis by DNA fragmentation ELISA. Data shown are representative of two
independent experiments. Bars represent the standard deviations resulting from triplicate samples (B) or duplicate reading of the same sample (C
and D). The extent of cell death in the vector line is arbitrarily set to 100%.
FIG. 5. PI3K activation of Akt alone is not sufficient to protect
RIE-1 cells from anoikis. (A) RIE-1 cells stably infected with the
plasma membrane-targeted and constitutively activated p110a subunit
of PI3K were assayed for Akt activation by Western blot analysis with
phospho-specific Akt antibodies after being held in suspension for 6 h
in the absence of serum. Blots were stripped and reprobed with anti-
Akt antibodies to determine total Akt levels. (B) Cells expressing
p110-CAAX were assessed for anoikis resistance by DNA fragmenta-
tion ELISA after 12 h of suspension. Data shown are representative of
two independent experiments. Bars represent the standard deviations
resulting from duplicate reading of the same sample.
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H-Ras(12V), activated PI3K (p110-CAAX), activated Rlf
(HA-Rlf-CAAX) or activated Raf (Raf-CAAX) were estab-
lished. While expression of H-Ras(12V) blocked anoikis of
ROSE cells, activated PI3K or activated versions of the other
two main Ras effectors, Raf and the RalGEF Rlf, failed to
block anoikis of ROSE cells (Fig. 6). These results suggest that,
unlike what has been observed with MDCK cells, PI3K signal-
ing is insufficient to block anoikis of at least two other epithe-
lial cell lines, namely, RIE-1 and ROSE 199 cells.
The Raf-MEK-ERK signaling pathway partially contributes
to anoikis resistance of RIE-1 cells. Although expression of
Raf-22W was previously shown to be insufficient to support
growth of RIE-1 cells in soft agar (35), inhibition of ERK
activation in Ras-transformed cells blocked growth in soft agar
(36). Therefore, we sought to test if Raf activation was neces-
sary for Ras-mediated anoikis resistance.
H-Ras(12V)-transformed RIE-1 cells showed elevated levels
of activated ERK when grown in suspension. Treatment with
30 mM U0126 MEK inhibitor reduced the level of ERK acti-
vation in control and H-Ras(12V)-transformed cells to below
basal activity (Fig. 7A). Interestingly, inhibition of ERK acti-
vation partially sensitized Ras-transformed RIE-1 cells to
anoikis. The response to inhibition of MEK was a gradual and
partial induction of apoptosis in suspended Ras-transformed
cells, which was substantially delayed relative to the apoptosis
observed for the control empty vector-infected cells (Fig. 7B).
Using DNA fragmentation ELISA, a more sensitive assay than
DNA laddering, the effects of U0126 were observed as early as
8 h postsuspension and continued to increase through the
latest time point tested, namely, 24 h (Fig. 7C).
One concern with these analyses is that the U0126 inhibitor
was overly effective at blocking MEK function and inhibited
basal levels of ERK phosphorylation that may be generally
required for cell viability. However, treatment of adherent
Ras-transformed RIE-1 cells with the same concentration of
U0126 did not cause any induction in apoptosis relative to
vehicle-treated controls (data not shown). Thus, while ERK
activation alone clearly is not sufficient to confer anoikis resis-
tance, the Raf-ERK signaling pathway partially contributes to
Ras-mediated inhibition of anoikis. This is in contrast to the
complete independence from Raf-MEK-ERK signaling de-
scribed previously for the resistance of MDCK cells to anoikis
(29).
Ras activation of the PI3K-Akt pathway is not involved in
transformation of RIE-1 cells. As described above, we found
that activation of the PI3K-Akt pathway alone was not suffi-
cient to block anoikis. Surprisingly, we found that Ras-trans-
formed RIE-1 cells did not possess up-regulated Akt activity
compared to empty vector-infected cells. The vector-infected
and H-Ras-transformed RIE-1 cells showed low levels of acti-
vated Akt when suspended in serum-free growth medium, and
the level of activated Akt increased comparably when these
cells were suspended in serum-containing growth medium
(Fig. 8A). Interestingly, while we found that the Akt activation
seen for vector-infected cells in the presence of serum was
inhibited by treatment with 10 mM LY29004, Akt activation
remained elevated in Ras-transformed cells. Nevertheless,
Ras-transformed RIE-1 cells were equally resistant to anoikis
when suspended either in the presence or in the absence of
serum (Fig. 8B). Thus, these data suggest that Ras fails to
activate Akt above vector controls and that activation of Akt is
not the means by which Ras-transformed RIE-1 cells become
resistant to anoikis.
Since we determined that PI3K activity does not appear to
play a role in anoikis protection of Ras-transformed cells, we
wanted to ascertain if PI3K signaling was also dispensable for
FIG. 6. Activated PI3K, Raf-1, or Rlf alone is not sufficient to block anoikis of ROSE 199 cells. ROSE 199 cells stably infected with pBabe-puro
retrovirus vectors encoding oncogenic H-Ras or the plasma membrane-targeted and constitutively activated versions of the p110a subunit of PI3K,
Raf-1, or HA-tagged Rlf were assayed for anoikis resistance after suspension for 4, 8, and 12 h by performing DNA fragmentation ELISA. Data
shown are representative of two independent experiments. Bars represent standard deviations resulting from duplicate reading of the same sample.
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the growth of Ras-transformed RIE-1 cells in soft agar. Ras-
transformed RIE-1 cells were suspended in soft agar in the
presence of 10 mM LY294002. After 10 days in suspension, the
number of colonies formed in the presence or absence of the
inhibitor was determined. As is apparent in Fig. 8C, LY294002
treatment failed to have a significant effect on the number or
size of the colonies formed. As expected, neither RIE-1 cells
stably expressing activated Raf nor such cells expressing PI3K
were capable of forming any colonies under these conditions.
These data emphasize that additional signaling properties of
Ras, independent of PI3K and Raf, are clearly required for
transformation of RIE-1 cells. Furthermore, these data suggest
that PI3K, which may play a central role for Ras transforma-
tion of some cell types, may be dispensable for transformation
of RIE-1 cells.
Combinatorial inhibition or coexpression of the Ras effec-
tors PI3K and Raf fails to affect anoikis resistance of RIE-1
cells. Previous work analyzing transforming properties of Ras
has shown that activated Raf and PI3K can cooperate and
cause synergistic transformation of fibroblast cells (43). Given
the precedent for a role for PI3K activation in anoikis protec-
tion in MDCK cells, and the partial role of ERK activation in
protecting Ras-transformed RIE-1 cells from anoikis, we
sought to determine if PI3K and Raf might cooperate to facil-
itate Ras-mediated anoikis resistance of RIE-1 cells.
We utilized two approaches to determine if Ras inhibition of
anoikis required the coordinate activation of Raf and PI3K.
First, we determined if the inhibition of both PI3K and Raf
signaling would cause a loss of anoikis resistance in Ras-trans-
formed RIE-1 cells. For these analyses, we treated control and
H-Ras(12V)-transformed RIE-1 cells in suspension with 30
mM U0126, 10 mM LY294002, or both inhibitors or with ve-
hicle for up to 12 h. Anoikis was measured by DNA fragmen-
tation ELISA. The limited reversal of anoikis protection seen
with U0126 treatment alone was not enhanced by concurrent
treatment with LY294002 (Fig. 9A). Thus, PI3K activation,
either alone or together with ERK activation, is not required
for Ras inhibition of anoikis.
For our second approach, we established mass populations
of RIE-1 cells stably expressing activated Raf-22W, p110-
CAAX, or both and compared their anoikis resistance to that
of Ras-transformed cells. Coexpression of constitutively active
PI3K and Raf was achieved by coinfection with retrovirus
expression vectors encoding Raf-22W (pZIP-raf-22W; G418
resistant) and p110-CAAX (pBabe-p110-CAAX; puromycin
resistant) and isolation of doubly infected cells by selection in
growth medium supplemented with G418 and puromycin.
Western blot analyses with phospho-specific antibodies veri-
fied that the doubly infected cells possessed enhanced Akt and
ERK activity (Fig. 9B). However, despite coactivation of ERK
and Akt, these cells were found to be anoikis sensitive (Fig.
9C). Interestingly, RIE-1 cells coexpressing either RalGDS-
CAAX or H-Ras(12V/G37) with Raf-22W were also found to
be as sensitive to anoikis as the vector controls (data not
shown). These data suggest that the effector signaling path-
way(s) that cooperates with Raf to cause Ras-mediated anoikis
resistance of RIE-1 cells is both PI3K and RalGEF indepen-
dent.
The EGFR autocrine signaling pathway critical to Ras
transformation of RIE-1 cells is dispensable for anoikis resis-
FIG. 7. ERK activation partially contributes to anoikis resistance of Ras-transformed RIE-1 cells. (A) RIE-1 cells expressing activated Ras were
suspended for 6 h in the presence of vehicle or 30 mM U0126 and assayed for ERK activation by immunoblotting with phospho-specific ERK
antibodies. Blots were stripped and reprobed with anti-ERK antibodies to determine total ERK levels. (B and C) The effects of pharmacologic
inhibition of ERK activation on anoikis were assessed by treating suspended cells with either U0126 (dark bars) or vehicle (light bars) for the
indicated time (hours) and performing DNA laddering (B) and DNA fragmentation ELISA (C) analyses. For panel C, only H-Ras(12V)-expressing
cells were assayed. Data shown are representative of at least two independent experiments. Bars represent the standard deviations resulting from
duplicate reading of the same sample.
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tance. We determined previously that oncogenic Ras transfor-
mation of RIE-1 cells involves upregulation of the expression
of TGF-a and related peptide growth factors that cause the
subsequent activation of the EGFR (20, 35). This autocrine
signaling loop is mediated by Raf-independent effector signal-
ing and is required for Ras transformation of RIE-1 cells.
Thus, we sought to determine if activation of this loop might
contribute to anoikis resistance of Ras-transformed RIE-1
cells.
We first determined if TGF-a stimulation of the EGFR
would provide any protection against anoikis. We treated sus-
pended parental RIE-1 cells with TGF-a in the presence or
absence of 2 mM PD153035, an EGFR kinase inhibitor, and
assayed for apoptosis. TGF-a treatment did cause a partial
inhibition of anoikis, and this activity was reversed by treat-
ment with the inhibitor (Fig. 10A). These results suggest that
activation of an EGFR autocrine loop alone has the potential
to contribute to Ras inhibition of anoikis.
Next, we determined if the EGFR autocrine loop was nec-
essary for Ras inhibition of anoikis. For these analyses, Ras-
transformed RIE-1 cells were treated with the PD153035
EGFR inhibitor as a function of time in suspension. The
PD153035 inhibitor was effective in blocking EGFR activity as
measured by its ability to block the anoikis-inhibitory signal
generated by TGF-a treatment (Fig. 10A). However, DNA
fragmentation ELISA revealed no significant induction of
apoptosis of Ras-transformed cells, compared with vector-
transfected control RIE-1 cells, over the course of 24 h (Fig.
10B). Thus, activation of an EGFR autocrine loop does not
contribute significantly to the anoikis-resistant phenotype of
Ras-transformed RIE-1 cells.
DISCUSSION
Oncogenic Ras utilizes multiple downstream effectors to
cause tumorigenic and malignant transformation of cells (7).
Hence, it is likely that distinct effectors will be involved in
mediating distinct aspects of neoplastic transformation. In this
study, we evaluated the role of the three best-characterized
effectors of Ras transformation, namely, Raf-1, PI3K, and Ral-
FIG. 8. Akt activation is not caused by Ras and is not involved in
protection against anoikis. (A) H-Ras(12V)-expressing RIE-1 cells
were held in suspension for 6 h in either the presence or the absence
of serum and treated with either 10 mM LY294002 or vehicle. Cells
were analyzed for activation of Akt by Western blot analysis with
phospho-specific Akt antibodies. Blots were stripped and reprobed
with anti-Akt antibodies to assess total Akt protein levels. (B) DNA
laddering was evaluated in cells suspended for 4 and 12 h in the
presence or absence of serum and treated with LY294002 or vehicle.
(C) RIE-1 cells stably infected with the empty pZIP-NeoSV(x)1 ex-
pression vector or vector encoding H-Ras(61L), Raf-22W, or p110-
CAAX were seeded in soft agar and assessed for colony formation
after 10 days. The dark bar represents cells treated with 10 mM
LY294002, and the light bar represents cells treated with vehicle.
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GEFs, in mediating inhibition of matrix deprivation-induced
apoptosis, or anoikis (18), of Ras-transformed RIE-1 cells.
First, we showed that parental RIE-1 cells underwent rapid
caspase-dependent anoikis, readily detectable within 4 h of
being placed in suspension, and that this response was over-
come by stable expression of oncogenic Ras. Second, we found
that constitutive activation of Raf-1 alone, or together with
PI3K or RalGDS activation, is not sufficient to inhibit anoikis
of RIE-1 cells. Inhibiting MEK activation with U0126, how-
ever, did partially restore anoikis sensitivity in Ras-trans-
formed cells, indicating that while the Raf-MEK-ERK pathway
is not sufficient, it does serve a necessary, albeit minor, role in
anoikis resistance. Third, we found that treatment with the
LY294002 PI3K inhibitor did not restore sensitivity to anoikis,
nor did it inhibit morphological or growth transformation, in-
dicating that PI3K may not be an important effector for Ras
transformation of RIE-1 cells. Finally, we found that the
EGFR autocrine growth loop, important for morphological
and growth transformation of RIE-1 cells, is not a significant
contributor to Ras inhibition of anoikis. Taken together, our
observations contrast with previous studies with MDCK canine
kidney epithelial cells, where the PI3K-Akt pathway was found
to be necessary and sufficient to block anoikis (29). Our results
emphasize the importance of cell context, even with respect to
two epithelial cell lines, in influencing the mechanisms by
which Ras promotes transformation.
Similar to observations with other epithelial cells, we found
that RIE-1 cells undergo anoikis and that activated Ras blocks
this apoptotic response. We found that the different Ras pro-
teins all show equivalent abilities to render RIE-1 cells resis-
tant to anoikis. Thus, while it has been reported previously that
H-Ras and K-Ras differentially activate Raf and PI3K (59),
these differences do not influence their abilities to block
anoikis in RIE-1 cells. Additionally, we found that activated
R-Ras and TC21/R-Ras2 also block anoikis but that activated
RhoA and Rac1 do not, providing some initial clues as to the
mechanism by which Ras might block anoikis. R-Ras has been
shown elsewhere to activate PI3K, but not Raf and RalGEFs
(34, 54). Similarly, we have found that TC21 can activate PI3K,
but not Raf or RalGDS (reference 21 and unpublished obser-
vations), although other investigators have reported that TC21
can activate Raf. Thus, the ability of TC21 and R-Ras to rescue
RIE-1 cells from anoikis suggests that a Raf- and RalGDS-
independent effector pathway(s) plays a critical role in block-
ing anoikis. Since Rho GTPases are activators of NF-kB (38,
53), it appears unlikely that this survival signal is sufficient to
mediate Ras inhibition of anoikis. The failure of activated
RhoA and Rac1 to block anoikis is also consistent with the
FIG. 9. Coordinate activation of Raf and PI3K is not necessary or
sufficient to block anoikis. (A) RIE-1 cells stably infected with empty
vector pBabe-puro (light bars) or encoding H-Ras(12V) (dark bars)
were treated with either vehicle or 10 mM LY294002 and/or 30 mM
U0126 for the indicated time in suspension (hours) prior to evaluating
anoikis by DNA fragmentation ELISA. (B) RIE-1 cells stably infected
with pBabe-p110-CAAX and pZIP-raf-22W were established by selec-
tion in growth medium supplemented with puromycin and G418. To
assay for the activation state of ERK and Akt, Western blot analyses
were performed with cells suspended for 6 h in the absence of serum.
Cells stably infected with the pZIP-NeoSV(x)1 and pBabe-puro empty
vectors were established as controls for these analyses. (C) The result-
ing cell populations were evaluated for anoikis by DNA fragmentation
ELISA after suspension for the indicated time (hours). Data shown are
representative of at least two independent experiments. Bars represent
the standard deviations resulting from duplicate reading of the same
sample.
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inability of these small GTPases to promote the anchorage-
independent growth of RIE-1 cells (data not shown).
To evaluate the specific role of Raf, PI3K, and RalGEFs in
mediating Ras inhibition of anoikis, we utilized both effector
domain mutants of Ras that are impaired in specific effector
function and constitutively activated versions of these effectors.
Consistent with our observation that R-Ras and TC21 can
protect RIE-1 cells against anoikis, we found that activation of
Raf (Raf-22W and the 12V/35S effector domain mutant) or
PI3K (p110a-CAAX and the 12V/40C effector domain mu-
tant) alone provided no protection against anoikis. Similarly,
expression of the 12V/37G effector domain mutant, an activa-
tor of RalGEFs, or constitutively activated RalGDS or Rlf also
failed to block anoikis. Thus, we conclude that the activation of
the Raf, PI3K, or RalGEF effector pathway alone is not suf-
ficient to block anoikis. We also found that activated Raf,
together with either activated PI3K or RalGDS, is still not
sufficient to block anoikis.
While other studies have also found that Raf activation
alone is not sufficient to block anoikis (29), our observations
with PI3K contrast with other studies that show a primary or
sole role for PI3K signaling in protecting Ras-transformed
epithelial cells from anoikis. Cumulatively, these data are more
likely to reflect cell-specific differences in the mechanisms of
Ras transformation than differences in experimental approach.
For example, our analyses of RIE-1 cells are essentially the
same as those used previously to implicate the key role for
PI3K in MDCK cells (29). We each expressed the H-Ras(12V/
C40) effector domain mutant that retains its ability to bind
PI3K or the plasma membrane-targeted p110a catalytic sub-
unit of PI3K in the respective cell lines and assayed for anoikis
resistance. While both constructs caused morphological trans-
formation of MDCK cells, we found that neither caused mor-
phological transformation of RIE-1 cells, suggesting that the
two epithelial cell lines respond fundamentally differently to
activation of the Ras effector PI3K. Finally, our use of the
inhibitor LY294002 failed to sensitize Ras-transformed RIE-1
cells to anoikis. This is in contrast to results obtained elsewhere
with MDCK and IEC-18 cells (29, 46), which were both made
sensitive to anoikis by treatment with the LY294002 compound
after transformation by Ras. We conclude that PI3K activation
is neither sufficient nor necessary for protection of RIE-1 cells
from anoikis.
Interestingly, while Downward and colleagues showed that
oncogenic Ras activates Akt in MDCK cells (29), we found no
such activation in RIE-1 cells, suggesting that Ras may not
activate PI3K robustly in this cell line. Furthermore, we also
saw no activation of Akt in suspended Ras-transformed ROSE
199 cells versus control empty-vector-transfected cells (data
not shown), despite the fact that expression of oncogenic Ras
confers anoikis resistance upon these cells as well. Interest-
ingly, some preliminary work with human carcinoma cell lines
also suggests that Ras may not utilize PI3K-Akt signaling to
confer anoikis resistance upon cancer cells. DLD-1 cells, a
human colon cell line with an endogenously mutated K-ras
allele, did not possess elevated levels of activated Akt relative
to DkS8 cells (which are derived from DLD-1 cells but have
lost the oncogenic ras allele by homologous recombination)
(data not shown). In fact, both DLD-1 and DkS8 cells have
barely detectable levels of Akt phosphorylation. DkS8 cells
have nonetheless regained some sensitivity to anoikis relative
to DLD-1 cells, suggesting that Ras promotes PI3K-indepen-
dent survival signaling in this human cell line. Correspond-
ingly, MDA 231 cells, a breast carcinoma cell line that also
contains an endogenously activated K-ras allele, show barely
detectable levels of Akt phosphorylation in suspension and yet
are anoikis resistant (L. B. Eckert and C. J. Der, unpublished
data). Furthermore, when treated with LY294002, these cells
are not sensitized to anoikis. Although it remains to be deter-
mined what signaling pathways contribute to anoikis resistance
of MDA 231 cells, these data clearly indicate that targeting
PI3K-Akt signaling in carcinomas that contain Ras mutations
may not cause inhibition of oncogenic Ras function. Other
researchers have also noted that Ras activation of PI3K and
Akt may be cell type specific and/or be sensitive to the level
and timing of expression of Ras and its effectors (16). Thus, in
contrast to the important contribution of PI3K to Ras trans-
formation of NIH 3T3 cells (43), PI3K may not be a critical
effector for Ras transformation of RIE-1 or ROSE cells. Fur-
thermore, our analyses of several human colon and breast
carcinoma cell lines indicate that Ras signaling to PI3K-Akt
FIG. 10. The TGF-a–EGFR autocrine loop is dispensable for
anoikis resistance mediated by Ras. (A) Parental RIE-1 cells were
treated with 10 ng of TGF-a/ml, 2 mM PD153035 EGFR kinase in-
hibitor, and/or vehicle for the indicated time (hours) in suspension
prior to evaluating the level of anoikis by DNA fragmentation ELISA.
(B) Cells expressing H-Ras(12V) or infected with the empty pBabe-
puro vector were assayed for anoikis by DNA fragmentation ELISA in
response to treatment with 2 mM PD153035 or vehicle.
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does not play a role in anoikis resistance of at least some
cancers that suffer Ras mutations in vivo.
Like the Ras effector PI3K, we observed a different role for
Raf in mediating anoikis resistance of Ras-transformed RIE-1
cells compared to other epithelial cells. Unlike what has been
reported elsewhere for MDCK and IEC-18 rat intestinal epi-
thelial cells (29, 46), inhibiting MEK in Ras-transformed
RIE-1 cells caused a partial reversion to an anoikis-sensitive
state. Expression of activated Raf, however, was not sufficient
to cause anoikis resistance of RIE-1 cells, even when coex-
pressed with activated PI3K or RalGEFs. Thus, Raf is likely to
cooperate with an unknown PI3K- and RalGEF-independent
effector(s) to block anoikis. Interestingly, cooperation between
two or more Ras effectors also appears to be required for
Ras-mediated anoikis resistance of IEC-18 cells (47), although
PI3K, and not Raf, appears to play a pivotal role in anoikis
resistance of these cells. Cooperation between Ras effectors
has also been observed for mediating other facets of transfor-
mation, for example, focus formation (43, 56). Thus, perhaps it
is not surprising that cooperativity exists between Ras effectors
in mediating anoikis resistance.
We found previously that a TGF-a–EGFR autocrine loop is
critical for complete transformation of RIE-1 cells, including
growth in soft agar (20). Consistent with this observation, we
found that activation of the EGFR with TGF-a is sufficient to
cause partial resistance to anoikis of suspended parental RIE-1
cells. Surprisingly, however, inhibition of EGFR signaling has
very little effect on anoikis resistance of Ras-transformed
RIE-1 cells, at least over the span of 24 h. Perhaps this signifies
that EGFR signaling plays a redundant role with a Ras effec-
tor(s) in inhibiting anoikis of Ras-transformed RIE-1 cells.
We have not yet identified what Ras effector(s) cooperates
with Raf to induce anoikis resistance of RIE-1 cells. In addi-
tion to Raf, PI3K, and RalGEFs, there is an expanding roster
of other proteins that interact with Ras in its activated, GTP-
bound state (51). These include AF-6, Nore-1, Rin1, PKCz,
MEKK1, RASSF1, and the Ras GTPase-activated proteins
(p120 and NF1). Although some of these proteins are unlikely
to play a role in inhibition of anoikis, for example, MEKK1,
whose activation is associated with induction of apoptosis (8),
none have thus far been tested for their ability to cooperate
with Raf in our study or other anoikis studies. However, since
Rin1 association is retained in the 37G effector domain mutant
(24) and AF-6 binding is retained in the 37G and 40C mutants
(28), it is unlikely that engagement of Rin1 and AF-6 is suffi-
cient to block anoikis. Perhaps the key effector for Ras inhibi-
tion of anoikis in RIE-1 cells remains to be identified.
How might Raf activity promote anoikis resistance of RIE-1
cells? Activation of the MAPK signaling pathway can inhibit
apoptosis in response to growth factor withdrawal, death re-
ceptor activation, and, as very recently described for fibroblasts
and MDCK cells, detachment from extracellular matrix (25,
32). Given the gradual and delayed sensitization of Ras-trans-
formed RIE-1 cells to anoikis in response to MEK inhibition,
one possible mechanism of action of this inhibitor is to cause
changes in gene expression that regulate apoptosis. Along
these lines, inhibition of MEK in mammalian cells can reduce
expression of several antiapoptotic proteins of the Bcl-2 family
as well as reduce expression of the antiapoptotic gene par-4 (2,
5). Alternatively, MEK signaling may have immediate effects
on the apoptosis machinery, for example, by modulating the
activation state of Bad (48). Whether the above-mentioned
consequences of MEK activation play a role in anoikis resis-
tance of Ras-transformed RIE-1 cells remains to be deter-
mined.
In summary, we have determined that PI3K is not a key
effector for Ras inhibition of anoikis or transformation in
RIE-1 cells. Furthermore, oncogenic Ras did not cause up-
regulation of the PI3K-Akt pathway in RIE-1 cells. Our results
emphasize that Ras promotes transformation in multiple ways
in a cell-context-dependent fashion. We are currently assessing
the importance of the Raf-ERK, PI3K-Akt, and other Ras
signaling pathways in protecting human tumor cells from
anoikis. We suspect that our studies will find a similar com-
plexity, with different Ras effector pathways playing important
roles in some, but not all, tumor cells. Thus, ultimately inhib-
iting oncogenic Ras function in various human tumors may
require effectively targeting a variety of Ras effector signaling
pathways.
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